[go: up one dir, main page]

NO20043842L - New crystal forms of atorvastatin hemicalcium and processes for their preparation, as well as new processes for the preparation of atorvastatin hemicalcium forms I, VIII and IX - Google Patents

New crystal forms of atorvastatin hemicalcium and processes for their preparation, as well as new processes for the preparation of atorvastatin hemicalcium forms I, VIII and IX

Info

Publication number
NO20043842L
NO20043842L NO20043842A NO20043842A NO20043842L NO 20043842 L NO20043842 L NO 20043842L NO 20043842 A NO20043842 A NO 20043842A NO 20043842 A NO20043842 A NO 20043842A NO 20043842 L NO20043842 L NO 20043842L
Authority
NO
Norway
Prior art keywords
preparation
processes
forms
atorvastatin hemicalcium
new
Prior art date
Application number
NO20043842A
Other languages
Norwegian (no)
Inventor
Judith Aronhime
Revital Lifshitz-Liron
Dalia Maidan-Hanoch
Limor Tessler
Nir Hasson
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of NO20043842L publication Critical patent/NO20043842L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/325—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • C07D207/327—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
NO20043842A 2002-02-15 2004-09-14 New crystal forms of atorvastatin hemicalcium and processes for their preparation, as well as new processes for the preparation of atorvastatin hemicalcium forms I, VIII and IX NO20043842L (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US35718102P 2002-02-15 2002-02-15
US42532502P 2002-11-12 2002-11-12
PCT/US2003/005384 WO2003070702A1 (en) 2002-02-15 2003-02-19 Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation, as well as novel processes for preparing atorvastatin hemi-calcium forms i, viii and ix

Publications (1)

Publication Number Publication Date
NO20043842L true NO20043842L (en) 2004-09-14

Family

ID=27760457

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20043842A NO20043842L (en) 2002-02-15 2004-09-14 New crystal forms of atorvastatin hemicalcium and processes for their preparation, as well as new processes for the preparation of atorvastatin hemicalcium forms I, VIII and IX

Country Status (14)

Country Link
EP (1) EP1480950A4 (en)
JP (2) JP2005519076A (en)
KR (1) KR100724515B1 (en)
CN (1) CN100406436C (en)
AU (1) AU2003217653A1 (en)
CA (1) CA2475864A1 (en)
DE (1) DE03713610T1 (en)
ES (1) ES2241507T1 (en)
HR (1) HRP20040768A2 (en)
IS (1) IS7402A (en)
MX (1) MXPA04007939A (en)
NO (1) NO20043842L (en)
PL (1) PL372303A1 (en)
WO (1) WO2003070702A1 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7411075B1 (en) 2000-11-16 2008-08-12 Teva Pharmaceutical Industries Ltd. Polymorphic form of atorvastatin calcium
IL156055A0 (en) 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
US7501450B2 (en) * 2000-11-30 2009-03-10 Teva Pharaceutical Industries Ltd. Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
HRP20040767A2 (en) 2002-02-19 2004-12-31 Teva Pharma Desolvating solvates of atorvastatin hemi-calcium
WO2004050618A2 (en) * 2002-11-28 2004-06-17 Teva Pharmaceutical Industries Ltd. Crystalline form f of atorvastatin hemi-calcium salt
US7655692B2 (en) 2003-06-12 2010-02-02 Pfizer Inc. Process for forming amorphous atorvastatin
US20050271717A1 (en) 2003-06-12 2005-12-08 Alfred Berchielli Pharmaceutical compositions of atorvastatin
JP2008506764A (en) 2004-07-20 2008-03-06 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー [R- (R *, R *)]-2- (4-fluorophenyl) -β, δ-dihydroxy-5- (1-methylethyl) -3-phenyl-4-[(phenylamino) carbonyl]- Novel form of 1H-pyrrole-1-heptanoic acid calcium salt (2: 1)
WO2006012499A2 (en) * 2004-07-22 2006-02-02 Teva Pharmaceutical Industries Ltd. Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation
WO2006048894A1 (en) * 2004-11-05 2006-05-11 Morepen Laboratories Limited Novel crystalline forms of atorvastatin calcium and processes for preparing them.
SK288276B6 (en) * 2005-04-08 2015-06-02 Egis Gyógyszergyár, Nyilvánosan Működő Részvénytársaság Process for preparation of crystalline atorvastatin hemicalcium salt polymorph form
ATE466840T1 (en) 2005-11-21 2010-05-15 Warner Lambert Co NEW FORMS OF ÄR-(R*,R*)Ü-2-(4-FLUORPHENYL)-B,D-DIHYDROXY-5-(-METHYLETHYL)-3-PHENYL-4-Ä(PHENYLAMINO)CARBONYLÜ-1H-PYRROLE -1-HEPTANIC ACID MAGNESIUM
TW200745026A (en) 2005-12-13 2007-12-16 Teva Pharma Crystal form of atorvastatin hemi-calcium and processes for preparation thereof
US20070265456A1 (en) * 2006-05-09 2007-11-15 Judith Aronhime Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
CN101657419A (en) * 2007-03-02 2010-02-24 东亚制药株式会社 Novel crystal forms of pyrrolylheptanoic acid derivatives
KR20120011249A (en) * 2010-07-28 2012-02-07 주식회사 경보제약 Novel crystalline forms of atorvastatin hemicalcium salts, hydrates thereof, and methods for preparing the same
KR101324862B1 (en) * 2011-07-12 2013-11-01 (주)에이에스텍 Spherical particle of clopidogrel bisulfate, pharmaceutical composition comprising the same and method of preparation thereof
PE20160945A1 (en) 2013-11-15 2016-09-26 Akebia Therapeutics Inc SOLID FORMS OF {[5- (3-CHLOROPHENYL) -3-HYDROXYPYRIDIN-2-CARBONYL] AMINO} ACID, COMPOSITIONS, AND USES OF THEM
CN105055357A (en) * 2015-09-25 2015-11-18 青岛华之草医药科技有限公司 Atorvastatin calcium composition tablet for treating hypercholesteremia
KR101723783B1 (en) * 2017-02-24 2017-04-07 주식회사 경보제약 Novel Crystal Form of Atorvastatin Hemi-Calcium, Hydrate thereof, and Method of Producing the Same
WO2025147589A1 (en) 2024-01-05 2025-07-10 Osanni Bio, Inc. Implants, compositions, and methods for treating retinal diseases and disorders

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP960313B1 (en) * 1995-07-17 2002-08-31 Warner Lambert Co Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1)
DE69634054T2 (en) * 1995-07-17 2005-12-08 Warner-Lambert Co. Crystalline (R- (R *, R *)) -2- (4-fluorophenyl) -β, δ-dihydroxy-5- (1-methylethyl) -3-phenyl-4 - ((phenylamino) carbonyl) -1H- Pyrrol-1-heptanecarboxylic acid hemi calcium salt (atorvastatin)
US6087511A (en) 1996-07-16 2000-07-11 Warner-Lambert Company Process for the production of amorphous [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl )-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid) calcium salt (2:1)
KR20020063190A (en) * 1999-11-17 2002-08-01 테바 파마슈티컬 인더스트리즈 리미티드 Polymorphic form of atorvastatin calcium
DE60026737T2 (en) * 1999-12-17 2006-09-21 Pfizer Science And Technology Ireland Ltd., Dun Laoghaire PROCESS FOR PREPARING CRYSTALLINE ATORVASTINE KALCIUM
EP1584616A1 (en) * 1999-12-17 2005-10-12 Pfizer Science and Technology Ireland Limited Industrial process for the production of crystalline atorvastatin trihydrate hemi calcium salt
JP2004513956A (en) * 2000-11-03 2004-05-13 テバ　ファーマシューティカル　インダストリーズ　リミティド Atorvastatin hemi-calcium type VII
IL156055A0 (en) * 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
DE60137364D1 (en) * 2000-12-27 2009-02-26 Teva Pharma CRYSTALLINE FORMS OF ATORVASTATIN
WO2002057229A1 (en) * 2001-01-19 2002-07-25 Biocon India Limited FORM V CRYSTALLINE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1- HEPTANOIC ACID HEMI CALCIUM SALT. (ATORVASTATIN)
CN1524073A (en) * 2001-06-29 2004-08-25 ����-�����ع�˾ ' R- (R, R) -2- (4-fluorophenyl) -beta, delta-dihydroxy-5- (1-methylethyl) -3-phenyl-4- (phenylamino) carbonyl-1H-pyrrole-1-heptanoic acid calcium salt (2: 1) (atorvastatin)
EP2292600A1 (en) * 2001-07-30 2011-03-09 Dr. Reddy's Laboratories Ltd. Crystaline forms VI and VII of atorvastatin calcium
UA77990C2 (en) * 2001-12-12 2007-02-15 Crystalline calcium salt of (2:1) [r-(r*,r*)]-2-(4-fluorophenyl)-?,?-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrroleheptanic acid
EP1562583A1 (en) * 2002-09-03 2005-08-17 Morepen Laboratories Ltd. Atorvastatin calcium form vi or hydrates thereof
WO2004050618A2 (en) * 2002-11-28 2004-06-17 Teva Pharmaceutical Industries Ltd. Crystalline form f of atorvastatin hemi-calcium salt

Also Published As

Publication number Publication date
IS7402A (en) 2004-08-13
EP1480950A1 (en) 2004-12-01
ES2241507T1 (en) 2005-11-01
PL372303A1 (en) 2005-07-11
KR100724515B1 (en) 2007-06-04
CA2475864A1 (en) 2003-08-28
CN1646490A (en) 2005-07-27
EP1480950A4 (en) 2005-05-18
JP2005519076A (en) 2005-06-30
WO2003070702A1 (en) 2003-08-28
AU2003217653A1 (en) 2003-09-09
MXPA04007939A (en) 2004-11-26
JP2009235083A (en) 2009-10-15
HRP20040768A2 (en) 2005-06-30
KR20040081202A (en) 2004-09-20
DE03713610T1 (en) 2005-10-20
CN100406436C (en) 2008-07-30

Similar Documents

Publication Publication Date Title
NO20043842L (en) New crystal forms of atorvastatin hemicalcium and processes for their preparation, as well as new processes for the preparation of atorvastatin hemicalcium forms I, VIII and IX
NO20032425D0 (en) New crystal forms of atorvastatin hemi-calcium and methods for their preparation, as well as new methods for the preparation of other forms
NO20035193D0 (en) New pyrrole derivatives as pharmaceuticals
NO20034187D0 (en) Novel spirotric cyclic derivatives and their use as phosphodiesterase-7 inhibitors
DK1701946T3 (en) 1-piperazine and 1-homopiperazine carboxylate derivatives, their preparation and their therapeutic use as inhibitors of the FAAH enzyme
NO20043726L (en) Heteroaryl compounds useful as inhibitors of GSK-3
NO20061396L (en) New heterocyclic compounds as HSP90 inhibitors
WO2005032472A3 (en) Pyrrolidine and piperidine derivatives as factor xa inhibitors
IS7768A (en) Methods for the production, isolation and purification of epothilone B, and the X-ray crystal structures of epothilone B
NO20050665L (en) Pyrrolidone derivatives as MAOE inhibitors
ATE412649T1 (en) SUBSTITUTED HETEROARYLBENZOFURANIC ACIDS
ATE486597T1 (en) 3,4-SUBSTITUTED PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF HYPERTENSION
NO20045554L (en) Procedure for the treatment of diabetes
NO20054876D0 (en) Substituted 4-phenyltetrahydroisoquinolines, process for their preparation, their use as drug and drug containing such compounds
HRP20150163T1 (en) PROCEDURE FOR THE PRODUCTION OF N-SUBSTITUTED 2-CYANOPYROLIDINE
NO20040996L (en) New Compounds and Compositions as Catepsin Inhibitors
NO20035328D0 (en) New compounds and preparations as catheps inhibitors
NO20070550L (en) Process for Preparation of Pyrrolotriazine Compounds
NO331195B1 (en) Process for the preparation of halogen-substituted monosulfides and their hydroxymonosulfide equivalents as intermediates.
DE602004023786D1 (en) Production of high purity alkylgallium
NO20055657D0 (en) Novel bioisosters of actinonin
NO20044332L (en) Improved process for the preparation of nevirapine
NO20050885L (en) New Process for the Synthesis of 1,3-Dihydro-2H-3-Benzazepin-2-One Compounds
NO20043610L (en) Phenylpyrimidinamines as IgE inhibitors
NO20053910L (en) New piperazine derivatives and their use as synthesis intermediates.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application